DEXA measures of body fat percentage and acute phase proteins among breast cancer survivors: a Cross-Sectional Analysis by Anne Dee et al.
Dee et al. BMC Cancer 2012, 12:343
http://www.biomedcentral.com/1471-2407/12/343RESEARCH ARTICLE Open AccessDEXA measures of body fat percentage and acute
phase proteins among breast cancer survivors:
a Cross-Sectional Analysis
Anne Dee1, Roberta McKean-Cowdin1*, Marian L Neuhouser2, Cornelia Ulrich2, Richard N Baumgartner5,
Anne McTiernan2, Kathy Baumgartner5, Catherine M Alfano3, Rachel Ballard-Barbash4 and Leslie Bernstein1,6Abstract
Background: C-reactive protein (CRP) and Serum amyloid A protein (SAA) increases with systemic inflammation
and are related to worse survival for breast cancer survivors. This study examines the association between percent
body fat and SAA and CRP and the potential interaction with NSAID use and weight change.
Methods: Participants included 134 non-Hispanic white and Hispanic breast cancer survivors from the Health,
Eating, Activity, and Lifestyle Study. Body fat percentage, measured with Dual Energy X-ray Absorptiometer (DEXA),
and circulating levels of CRP and SAA were obtained 30 months after breast cancer diagnosis.
Results: Circulating concentrations of CRP and SAA were associated with increased adiposity as measured by DEXA
after adjustment for age at 24-months, race/ethnicity, dietary energy intake, weight change, and NSAID use.
Survivors with higher body fat ≥35% had significantly higher concentrations of CRP (2.01 mg/l vs. 0.85 mg/l) and
SAA (6.21 mg/l vs. 4.21 mg/l) compared to non-obese (body fat < 35%). Women who had gained more than 5% of
their body weight since breast cancer diagnosis had non-statistically significant higher geometric mean levels of
CRP and SAA. Mean levels of CRP and SAA were higher among obese women who were non-users of NSAIDs
compared to current users; the association with SAA reached statistical significance (Mean SAA = 7.24, 95%CI
6.13-8.56 for non-NSAID; vs. 4.87; 95%CI 3.95-6.0 for NSAID users respectively).
Conclusions: Breast cancer survivors with higher body fat had higher mean concentrations of CRP and SAA than
women with lower body fat. Further assessment of NSAID use and weight control in reducing circulating
inflammatory markers among survivors may be worthwhile to investigate in randomized intervention trials as
higher inflammatory markers are associated with worse survival.Background
C-reactive protein (CRP) and serum amyloid A (SAA)
are nonspecific acute-phase proteins that increase in
response to systemic inflammation [1]. The high levels
of these proteins among the obese (BMI > 30) may indi-
cate a low-grade chronic inflammatory condition, which
could result from the expansion of blood vessels and
other supporting structures necessary for growth of adi-
pose tissue [2]. Obese individuals have been shown to
have higher circulating levels of pro-inflammatory* Correspondence: mckeanco@usc.edu
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reproduction in any medium, provided the orcytokines (e.g. TNF-α and IL-6) and acute-phase pro-
teins (including CRP and SAA) [3]. About one-third of
circulating IL-6 comes from adipose tissue, which is also
proportionally and positively associated with the over-
expression of TNF-α [4,5]. The pro-inflammatory cyto-
kine IL-6 has a dramatic impact on the secretion of
acute-phase proteins by the liver and may result in a 10
to 100 fold increase in circulating CRP and SAA [6].
The inflammatory process is considered critical to both
the development and progression of cancer [7,8]. Ele-
vated circulating levels of CRP [9] and SAA [10] have
been associated with greater probability of breast
cancer death and with more advanced disease stage at
diagnosis [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adiposity and concentrations of CRP and SAA have
used anthropometric measures of obesity including body
mass index (BMI, kg/m2), waist circumference, and bio-
electrical impedance [2,12-14]. One small (N = 61) study
of obese, white women found a positive association
(p < 0.005) between plasma CRP and total body fat mass
using Dual Energy X-ray Absorptiometry (DEXA) [15].
In our analysis, we measured body fat among breast can-
cer cases selected irrespective of weight. We selected
DEXA as our primary measure of adiposity as it provides
a highly valid and reliable estimate of total body fat in
postmenopausal women, because it incorporates mea-
sures of bone mineral mass, lean soft tissue, and fat
mass [16,17].
We investigated the relationship between body fat per-
centage and systemic inflammatory markers among a
sample of Hispanic and non-Hispanic White breast can-
cer survivors enrolled in the HEAL (Health, Eating, Ac-
tivity and Lifestyle) Study by using fat percentage
assessed by DEXA and CRP/SAA measurements from
samples taken at the same assessment. We explored
whether the association between obesity and CRP/SAA
in breast cancer survivors differs by modifiable lifestyle
factors, such as weight change, or use of NSAIDs. While
the biological mechanism is not known, elevated con-
centrations of post-diagnostic serological CRP and SAA
and high post-diagnostic BMI have been associated
with poor prognosis in breast cancer patients [10,18],
therefore it is important to understand the factors that




The data for this analysis were collected for the HEAL
Study, a population-based prospective cohort of breast
cancer survivors which includes women who were diag-
nosed with in-situ to stage IIIa breast cancer from 1996
through 1999. Baseline data were collected within the
first year after diagnosis, on average 7.5 months post
diagnosis and follow-up data were collected approxi-
mately 24 months after baseline. The HEAL study
included 1,183 women, 18 years of age or older, who
were identified through the Surveillance, Epidemiology,
and End Results (SEER) registries in New Mexico, Los
Angeles County, California and western Washington. Of
these, 615 women were recruited from New Mexico, 202
from Washington and 366 from Los Angeles. This
observational study was designed to evaluate the inde-
pendent roles of sex-hormones, diet, weight, physical
activity, genetics, and other factors on post-diagnostic
breast cancer prognosis and survival. Details of study
design and recruitment procedures have been describedpreviously [12,19,20]. The study was conducted at par-
ticipating centers with the approval of respective Institu-
tional Review Boards according to an assurance filed
and approved by the U.S. Department of Health and
Human Services.
The current analysis was restricted to a sub-set of
HEAL participants who had body composition measured
by DEXA approximately 24 months following the initial
assessment when most women had completed breast
cancer treatment. Measurements of inflammatory mar-
kers (CRP/SAA) were tested at 24 months follow-up,
but not at baseline. Of the 1,183 HEAL participants, 608
women completed DEXA at baseline and funds were
available to conduct DEXA measurements on 155 of these
patients (135 from New Mexico, 20 from Washington)
at the 24 month follow-up examination. The 134
women eligible for this analysis included 17 from
Washington and 117 from New Mexico who were
self-identified as non-Hispanic White (n=105) or Hispanic
(n = 29). A flowchart showing reasons for exclusion is
shown in Figure 1.
Clinical variables
Trained staff at the respective study centers obtained
waist and hip circumferences (in centimeters) at baseline
and at the 24 month follow-up visit. Waist circumfer-
ence was measured just above the superior margin of
the iliac crests. Hip circumference was measured at the
maximal posterior projection of the buttocks.
Body fat mass was measured using DEXA for the New
Mexico and western Washington study centers at base-
line and at the 24 month follow-up examinations. The
Los Angeles Study center did not obtain DEXA mea-
sures. A whole body DEXA scan uses the differential
attenuation of two low dose x-ray beams to partition
total body mass into bone, lean and fat soft tissue com-
ponents based on established mass-attenuation con-
stants for bone mineral and lipid. Percent body fat is
calculated using the bone, lean, and fat mass to estimate
total fat mass divided by measured weight x 100. Mea-
surements were taken from participants in New Mexico
using the Lunar model DPX (GE Medical Systems,
Milwaukee, WI) and in Washington using the Hologic
model QDR 1500 (Hologic Inc, Waltham, MA). The
technical error of precision for the measurement of fat
mass using these devices is approximately 1.5% [21].
Furthermore, we calculated BMI using height and weight
measured at the same time as the DEXA was performed
at baseline and at 24 months of follow-up.
Circulating concentrations of CRP and SAA were mea-
sured by latex-enhanced nephelometry using highly sen-
sitive assays on the Behring Nephelometer II analyzer
(Dade Behring Diagnostics, Deerfield, IL) at the Univer-
sity of Washington. Tests were completed using fasting
Figure 1 Definition of study population and exclusion criteria.
Flow chart of the population analyzed within the HEAL cohort.
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assessment. Each sample was processed within 3 hours
of collection and stored at −70° to −80°C until analysis.
Interassay coefficients of variation were 5% to 9%
for CRP and 4% to 8% for SAA. The lowest detect-
able value for CRP is 0.2 mg/L; the lowest for SAA is
0.7 mg/L. The control materials that were included with
assay batches for quality control purposes came from
Bio-Rad Laboratories (Hercules, CA).
Questionnaire variables
In-person interviews (New Mexico) and self-administered
questionnaire forms (Washington) provided information
on demographics, dietary intake, menopausal status,
smoking status, disease history (arthritis, chronic lung dis-
ease, diabetes, heart attack, heart failure, hypertension,
other cancers) and current use of any over the counter or
prescription NSAIDs at the 24-month follow-up survey.
Cancer treatment history, including history of radiation,
chemotherapy and tamoxifen use, was obtained throughmedical record review, participants’ SEER records, or
responses to the questionnaire. Weight gain is defined as
an increase of more than 5% in body weight from the
baseline to the follow-up exam and weight loss is defined
as decrease of more than 5% in body weight from base-
line to follow-up at 24 months [22].
Physical activity was assessed using the Modifiable
Activity Questionnaire developed by Kriska and col-
leagues [23]. The type, duration, and frequency of activ-
ities performed in the past year were evaluated at the
baseline and at the 24 month assessment. Hours of
activity per week for each activity type were calculated
by multiplying the frequency of each activity by the dur-
ation. Activities were further classified by intensity –
light (<3 METs), moderate (3–6 METs) or vigorous
(>6 METs) – based on the assignment of MET values to
activities by the Compendium of Physical Activities [24].
A metabolic equivalent task (MET) is defined as the ratio
of the associated metabolic rate for a specific activity
divided by the resting metabolic rate (RMR). A summary
measure of activity duration and intensity (restricted to
moderate intensity and vigorous intensity exercise activ-
ities and defined as the sum of each activity’s MET value
times hours per week) was created and used.
Energy intake was estimated using data from the
Women’s Health Initiative food frequency questionnaire
and the nutrient database from the University of Minne-
sota’s Nutrition Coordinating Center’s Nutrition Data
Systems for Research (NDS-R, version 2005) [25].
Women at the New Mexico study site were asked their
usual dietary intake in the preceding year, while women
at the Washington site were asked about their intake in
the preceding month.
Statistical analyses
Values of CRP and SAA were logarithmically trans-
formed due to the skewed distribution of the data. Geo-
metric means and 95% confidence intervals (CI) were
calculated for CRP and SAA concentrations by obesity
status as defined by DEXA measurements (<35% versus
≥35% body fat [26]). β coefficients and 95% CIs were cal-
culated from linear regression models to assess the asso-
ciations between percent body fat and continuous values
of CRP and SAA. Age, race/ethnicity, NSAID use at
24 month follow-up assessment; menopausal status at
24 month follow-up; history of chemotherapy, arthritis,
hypertension, smoking, alcohol intake, energy intake at
24 month follow-up assessment; weight change between
baseline and 24 month follow-up assessments; study
center; physical activity at 24 month follow-up assess-
ment, and change in physical activity between baseline
and 24 month follow-up assessment were considered as
potential effect modifiers and confounders in the models.
All final models were adjusted for age at 24-months,
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ous), weight change (kg continuous), and NSAID use
(yes/no). Other covariates were not included in the final
model as they did not substantially affect our results with
the exception of history of arthritis in the models for
SAA. The Scheffé multiple comparison procedure (overall
p < .05) was used to compare differences across groups.
Participants were classified as obese if their body fat
percentage was equal to or greater than 35%, which is
the standard used by most clinicians [26]. It has been
described as approximately equivalent to a BMI of
25 kg/m2 or above in white women ages 40–59 years,
however older women may have higher percent
body fat associated with the same BMI [27]. Physical
activity cutpoints are based on recommended activity
for weight maintenance in METS (<13MET hr/wk,
13-26MET hr/wk, >26MET hr/wk) [28]. Smoking his-
tory at the 24 month follow-up assessment was classi-
fied as never smoked, smoked ≤6 months ago, and
smoked >6 months ago, as we suspected that time since
cessation of smoking might influence CRP or SAA
levels at blood draw. Alcohol consumption at the
24 month follow-up assessment was defined as none,
<10gm of alcohol, and >10gm of alcohol per day [29].
Regression analyses were used to determine the asso-
ciations between CRP or SAA and BMI as well as to de-
termine the associations between CRP or SAA and
DEXA. The results for these two different anthropo-
morphic measures were compared. Correlations of con-
tinuous BMI values and percent body fat values
measured by DEXA with loge(CRP) and loge(SAA) were
examined. Statistical analyses were performed using SAS
version 9.2 (SAS Institute Inc, North Carolina, USA).
Results
Table 1 shows that breast cancer patients who were
obese (i.e., body fat >35%) were more likely to be older
(p < .0001), post-menopausal (p < .0001) withlarger aver-
age hip circumference (p < .0001) and larger average
waist circumference (p < .0001) than women who were
not obese. Despite these differences, there is an overlap
in the weight ranges for the non-obese and obese (body
fat >35%); the ranges were 46.0 kg - 71.0 kg and
51.0 kg-104 kg, respectively. An overlap in weight is also
observed when stratifying based on BMI (obese >30 BMI) -
the range for the non-obese is 17.4 kg/m2- 30.2 kg/m2
and for the obese, 20.9 kg/m2- 42.2 kg/m2.
History of arthritis (p < .0001) and hypertension
(p = 0.04) were significantly associated with obesity but
there were no differences in several other conditions (i.e.
chronic lung disease, diabetes, heart attack or heart fail-
ure, and hypertension) that were not common in the
study population (data not shown). Obesity status was
not associated with demographic or lifestyle factorsincluding alcohol consumption, smoking history, or edu-
cation level (data not shown) and, the proportions of
obese and non-obese survivors who gained 5% or more
of their bodyweight over the two year follow-up period
were similar (25.3% vs. 25.6%). Neither tamoxifen ther-
apy nor past treatment with chemotherapy was asso-
ciated with obesity status. However, obese women were
more likely to report current use of any prescription
or over the counter NSAID at the 24 month follow-up
assessment (p = .02).
Geometric mean CRP concentrations were signifi-
cantly higher among obese than non-obese women
(Table 2). In this table, stratum specific geometric means
labeled with different numbers (1–3) are statistically sig-
nificantly different from one another based on Scheffé
multiple comparison procedures; values for CRP and
SAA were tested separately. Obese women had higher
CRP values than non-obese women among those who
did not use NSAIDS compared to those who used
NSAIDS. In the same way, women who gained weight
from baseline to the 24-month follow-up assessment
had higher mean levels of CRP than women who did not
gain weight; however, these differences did not reach
statistical significance. No significant differences were
observed by smoking history, physical activity, or caloric
intake (data not shown). We observed a dose–response
relationship between CRP and tertile of percent body
fat in all women (i.e. not obese and obese) combined
(p < .001, data not shown). The significant positive trend
persisted after adjustment for NSAID use, level of caloric
intake, and history of arthritis (data not shown).
Similar to our findings for CRP, geometric mean levels
of SAA were significantly higher for obese than non
obese participants (Table 2). Further, mean SAA concen-
trations were significantly higher among obese women
not taking NSAIDs compared to women taking them.
Higher geometric mean concentrations of SAA also were
found for women who gained weight from baseline to
the 24-month assessment, but these associations did not
reach statistical significance. These associations were not
significantly altered in a model that additionally adjusted
for study site (data not shown). The associations
observed were similar when using an obesity cut-point
of ≥ 41% body fat as proposed by Gallgather et al. (data
not shown) [27].
Figure 2 presents the plot for loge (CRP) versus per-
cent body fat centered on the mean. We observed an
approximate linear relationship between loge (CRP) and
percent body fat, both in an unadjusted model and after
adjusting for age, energy intake, weight difference, race/
ethnicity and NSAID use. Our linear regression model
indicates that the estimated CRP increases by 1.07 mg/L
for each 1% increase in body fat beyond the mean.
At the mean percent body fat of 38.9%, the estimated






Characteristics at 24 month post-diagnosis assessment
CRP (mg/L), Mean (SD) 1.2 (1.5) 3.4 (3.7) <.0001
SAA (mg/L), Mean (SD) 4.2 (2.2) 9.3 (17.9) 0.008
Age at assessment, Mean (SD) 53.2 (8.8) 61.4 (10.3) <.0001
Postmenopausalb- yes, n (%) 18 (52.6) 81 (91.0) <.0001
Weight (kg)c, Mean (SD) 58.9 (7.2) 74.3 (12.1) <.0001
BMI (kg/m2), Mean (SD) 21.9 (2.5) 28.4 (4.3) <.0001
Percentage of body fat, Mean (SD) 29.7 (5.0) 42.6 (4.7) <.0001
Hip Circumference (cm), Mean (SD) 96.0 (5.5) 110 (9.3) <.0001
Waist (cm), Mean (SD) 74.2 (7.2) 92.4 (11.2) <.0001
Weight Change, n (%) 0.06
Loss 7 (18.0) 5 (5.3)
No Changed 22 (56.4) 66 (69.5)
Gain 10 (25.6) 24 (25.3)
Physical Activity (MET hrs/week), n (%) 44.7 (45.4) 28.2 (24.9) 0.04
Change in Physical Activity since baselinee (MET-hrs/week) 6.7 (29.5) -5.3 (31.6) 0.04
History of Arthritis – yes, n (%) 5 (12.8) 50 (52.6) <.0001
Hypertensionf 6 (15.4) 31 (33.0) 0.04
Past and current medication use - yes, n (%)
Tamoxifeng 14 (35.9) 41 (43.2) 0.44
NSAID 8 (20.5) 40 (42.1) 0.02
Chemotherapyh 9 (23.1) 19 (20.0) 0.69
a Obese ≥35% Body Fat, not obese < 35% Body Fat.
b I non obese and 6 obese excluded due to unknown menopausal status.
c Weight at follow-up is taken at the second DEXA measurement.
d Weight change within 5% change in body weight since baseline.
e Baseline is approximately 6 months post-diagnosis. Follow-up is approximately 30 months post-diagnosis.
f 1 obese participant answered "Don't know" and was excluded.
g Current use of tamoxifen or over the counter or prescription non-steroidal anti-inflammatory drug (NSAID).
h 2 non-obese participants refused to answer and were excluded.
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slopes (βs) for the unadjusted and adjusted models
were similar.
Figure 3 presents the plot for loge (SAA) versus per-
cent body fat centered on the mean; we found that for
every 1% increase in body fat above the mean, estimated
SAA increased 1.03 mg/L. At the mean body fat percent-
age of 38.9%, the estimated SAA is 5.6 mg/L.
Table 3 describes the β coefficients and 95% confidence
intervals (CIs) for the regression models describing the re-
lationship between percent body fat and loge (CRP) and
loge (SAA). The β coefficients represent the increase in
loge (CRP) or loge (SAA) per 1% increase in body fat. The
values for the overall model and those stratified by NSAID
use, history of arthritis, and weight change are shown. No
significant interaction was found between percent body fat
and NSAIDS, history of arthritis, weight change (Table 3),
or any lifestyle or health-related factor. When westratified by recent NSAID use, we found a greater
increase in loge (CRP) for each 1% increase in body fat
for women who did not take NSAIDs compared with
women who did. The results for loge (SAA) are generally
similar to those described for loge (CRP), although the dif-
ferences in β coefficients are smaller between the strata.
We examined the distribution of acute phase proteins
(loge CRP, loge SAA) by continuous measures of DEXA
(% body fat) or BMI (data not shown) all measured at
the same follow-up visit. The distributions for percent
body fat and BMI were similar, however we observed
slightly less clustering of data points for DEXA measures
than for BMI, when plotted against the two acute phase
proteins. The correlation coefficients for loge (CRP) with
DEXA were 0.52 (0.39-0.63) compared to 0.47 (0.34-0.60)
for BMI. Similarly, the correlation coefficient for loge
(SAA) were 0.42 (0.27-0.54) for DEXA compared to 0.38
(0.22-0.42) for BMI.
Table 2 Adjusted geometric means and 95% CI of CRP and SAA stratified by obesity status at 24-month follow-up
assessment (n =134)
Stratifying variablea CRP Mean (95%CI) SAA Mean (95%CI)
Not obese (N= 39) Obeseb (N =95) Not obese (N= 39) Obese (N =95)
Overall 0.85 (0.61-1.20)1 2.01 (1.64-2.46)2 4.21 (3.34-5.30)1 6.21 (5.42-7.11)2
NSAID usec
No (n = 31/55)d 0.84 (0.58-1.21)1 2.31 (1.78-3.00)2 4.29 (3.36-5.48)1 7.24 (6.13-8.56)2
Yes (n = 8/40) 0.99 (0.49-1.97)1,2 1.64 (1.20-2.23)1,2 4.59 (2.93-7.19)1,2 4.87 (3.95-6.00)1
History of arthritis
No (n = 34/45) 0.81 (0.57-1.17)1 1.89 (1.41-2.52)2 3.70 (2.93-4.67)1 5.37 (4.46-6.47)1,2
Yes (n = 5/50) 0.91 (0.38-2.18)1,2 2.19 (1.65-2.90)2 4.06 (2.31-7.16)1,2 7.75 (6.46-9.31)2
Weight Changee
Loss (n = 7/5) 0.75 (0.36-1.57)1,2 1.96 (0.81-4.78)1,2 3.11 (1.94-4.98)1 5.27 (2.97-9.35)1,2
No Change (n = 22/66) 0.70 (0.46-1.07)1 1.93 (1.51-2.47)2 4.28 (3.23-5.67)1,2 5.88 (4.99-6.92)1,2
Gain (n = 10/24) 1.12 (0.59-2.12)1,2 2.50 (1.69-3.69)2 4.51 (2.97-6.86)1,2 7.81 (6.07-10.04)2
a Scheffé multiple comparison procedure (p < .05) was used to compare differences across groups. For each variable means with different numbers (1-3) are
statistically different form one another and evaluated separately for CRP and SAA.
CRP means are adjusted for age, race/ethnicity, energy (kcal), NSAID (yes/no), and weight difference (kg), SAA means are additionally adjusted for arthritis (yes/no).
b Obese ≥35% Body Fat, not obese < 35% Body Fat.
c Current use of over-the-counter or prescription non-steroidal ant-inflammatory drugs (NSAID). Adjusted for age, ethnicity, energy (kcal), weight difference (kg).
d Sample size (n) represents number of non-obese and obese women in each stratum. e.g. 31 non-obese and 35 obese women who are non-users of NSAID.
The same formatting in describing sample size is used for other strata.
e Adjusted for age, ethnicity, energy (kcal), NSAID (yes/no). Weight gain is >5% increase in bodyweight since baseline and weight loss is >5% decrease since
baseline.
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In this cohort of breast cancer survivors, we found a sig-
nificant association between acute phase proteins (CRP
or SAA) and adiposity as measured by DEXA. Women
with higher measures of adiposity had higher CRP and
SAA concentrations compared to women with lowerFigure 2 Scatterplot and predicted regression line of loge(CRP) cente
line of loge(CRP) centered on body fat percentage on a sample of 134 brea
intake (kcal), weight difference(kg), and NSAID use.adiposity regardless of lifestyle or medical factors. Our
analysis indicates that percent body fat as measured by
DEXA is a strong predictor of CRP and SAA levels.
Furthermore, our data suggest recent use of NSAIDS
modifies the observed association of adiposity with
acute phase proteins. We found that obese women whored on body fat percentage. Scatterplot and predicted regression
st cancer survivors from the HEAL study controlling for age, caloric
Figure 3 Scatterplot and predicted regression lines of loge(SAA) centered on body fat percentage. Scatterplot and predicted regression
lines of loge(SAA) centered on body fat percentage on a sample of 134 breast cancer survivors from the HEAL study controlling for age, history of
arthritis, caloric intake (kcal), weight difference(kg), and NSAID use.
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mean concentrations of SAA than women who did not
use NSAIDS. A similar pattern was found for CRP,
although the association did not reach statistical signifi-
cance. The potential modifying effects of weight change
did not reach statistical significance for SAA or CRP,
perhaps because small numbers of women in some of
the strata limited statistical power.
DEXA may provide a more accurate measure of body
fat for studies of acute phase proteins than other
anthropometric measures because DEXA can distinguish
between bone, muscle and fat mass [30]. The accuracy
of BMI as a measure of percent body fat may vary byTable 3 Linear regression models for loge(CRP) and loge(SAA)
loge(CRP)
β SE 95%CI
Full Modela 0.068 0.012 (0.04,0.09)
NSAID use (n = 48)b 0.037 0.027 (-0.02,0.09)
No NSAID use (n = 86) 0.076 0.013 (0.05,0.10)
History of arthritis (n = 55) 0.057 0.024 (0.01,0.11)
No History of arthritis (n = 79) 0.069 0.015 (0.04,0.10)
Weight Changec
Loss (n = 12) 0.128 0.229 (-0.43,0.69)
Same (n = 88) 0.079 0.013 (0.05,0.10)
Gain (n = 34) 0.048 0.026 (-0.01,0.10)
a loge(CRP) model is adjusted for age, ethnicity, energy (kcal), NSAID (yes/no), and w
(yes/no).
b Current use of over-the-counter or prescription non-steroidal ant-inflammatory dru
c Adjusted for age, energy (kcal), NSAID (yes/no). Weight gain is >5% increase in boage, gender, race or ethnicity and physical conditioning.
It is an overall measure of body mass and does not pro-
vide measures of body composition. Thus, there is no
absolute cross-tabulation for the DEXA definition of fat
by standard BMI. Body fat determined through clinical
measures of bio-impedance also may be less reliable
than DEXA, as the measure tends to underestimate adi-
posity [16,17]. Additionally, while BMI, waist-hip ratio,
and waist circumference have been used as indicators of
body fatness, these measurements were found to be
more closely correlated with each other than with body
fatness measured by DEXA based on data from a nation-
ally representative US population sample (Nationalon body fat percentage overall and stratified (n = 134)
loge(SAA)
p interaction β SE 95%CI p-interaction
0.032 0.008 (0.02,0.05)
0.13 -0.005 0.023 (-0.05,0.04) 0.16
0.032 0.008 (0.02,0.05)






eight difference(kg). loge(SAA) model is additionally adjusted for arthritis
gs (NSAID). Adjusted for age, race/ethnicity, energy (kg) weight difference (kg).
dyweight since baseline and weight loss is >5% decrease since baseline.
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HEAL sample, we were not able to distinguish differ-
ences in correlation between acute phase proteins (i.e.
CRP or SAA) and DEXA or BMI, possibly due to the
small sample.
The association between acute phase proteins and adi-
posity we found is consistent with earlier reports based
on anthropometric measures that found increased
adiposity was significantly correlated with elevated levels
of CRP and SAA among breast cancer patients [14,31].
A previous study of HEAL participants (n = 741) using
anthropometric measures (BMI, waist circumference)
found significant associations between BMI and inflam-
matory proteins [14]. The association of percent body
fat with levels of acute phase proteins suggests that
circulating inflammatory markers are associated with
greater adiposity and not just greater weight.
We also found a suggestive association between weight
gain and circulating acute phase proteins in our sample.
If this association is causal, weight control or weight loss
may be one mechanism for controlling elevated levels of
circulating inflammatory proteins in breast cancer survi-
vors. However, one concern related to unmonitored
weight loss in breast cancer survivors is sarcopenia [32],
and the potential impact of concomitant fat and muscle
loss on survival. In HEAL participants, sarcopenic
women were approximately 3 times as likely to die from
any cause and 2 times as likely to die from breast cancer
as women without sarcopenia [33]. Therefore, any efforts
to maintain or lose weight would need to focus on
retaining lean body mass while maintaining or losing
body fat [32,34].
In the literature, weight loss and physical activity have
inconsistently been associated with circulating acute
phase proteins. A study of obese individuals found that
weight reduction following caloric-restriction was asso-
ciated with reduced plasma CRP levels [15]. One study
found that weight loss was associated with a significant
reduction in IL-6 levels in both plasma and adipose; the
authors also found a non-statistically significant reduc-
tion in CRP [35]. Bochud et al. suggested that the lack of
statistical significance with CRP in this study may be
due to the short duration of weight loss and the overall
small amount of weight lost [31]. However, a subsequent
intervention study involving 40 overweight breast cancer
survivors showed no association between weight loss
and CRP [36]. With respect to physical activity, it has
been indicated that aerobic exercise may be more effect-
ive than flexibility or resistance training for CRP reduc-
tion [37]. The absence of differences in effect by physical
activity in the current study may be due to our small
sample or that the type or level of exercise was not ad-
equately variable to produce a measurable effect. A large
proportion of HEAL participants reported high levels ofphysical activity, such that even the obese participants
reported an average of 28.5 MET-hours per week
of activity.
Our data suggest that use of NSAIDs may be one way
to control circulating levels of CRP/SAA in breast
cancer survivors. Additional data from randomized inter-
vention trials are needed to confirm this potential bene-
fit. One concern is that a meta-analysis of the available
evidence on cardiovascular safety of NSAIDs found that
use of some types of NSAIDs were associated with ele-
vated risk of myocardial infarction, stroke, and cardiovas-
cular death [38]. However, cardiovascular risk varies by
type of NSAID [38], which in some cases may be pro-
tective (e.g. aspirin). An analysis of data from the Nurses'
Health Study (n = 4,164) found that aspirin use is asso-
ciated with decreased risk of breast cancer specific death
and death from any cause in breast cancer patients [39].
A meta-analysis also showed daily use of aspirin reduced
incidence and metastasis of colorectal cancers and sev-
eral other cancers including breast cancer [40,41]. Thus,
further assessment of the association between NSAID
such as aspirin and acute phase proteins in breast cancer
survivors may be of value, as lower levels of CRP
have been linked with longer survival and NSAIDs have
been suggested as an adjuvant treatment for breast
cancer [42].
A strength of this study is the use of DEXA measure-
ment as a precise estimate of adiposity. Our study
includes both non-Hispanic white and Hispanic breast
cancer survivors. Differences in percent body fat and
CRP or SAA levels by race/ethnicity may be expected
due to previous studies that have indicated fat-patterning
differs by race and ethnicity. Specifically, higher mea-
sures of central adiposity have been found in Hispanic
women [43]. Since higher CRP and SAA levels adversely
affect survival among breast cancer survivors, using a
more precise measure of body fat (a predictor of CRP
and SAA) may be useful for accurately identifying those
women who could improve prognosis by decreasing
body fat [10].
The primary limitation of this study is that despite
being the largest study to date with comprehensive mea-
sures of body composition, BMI and inflammation, it
remains a relatively small study. Therefore, a lack of
difference in stratified analyses to examine the effects of
various lifestyle factors and medical conditions must be
interpreted with caution as statistical power is limited.
The wide variance in weight and adiposity measures also
is a limitation. Other limitations in our methods that
may make associations more difficult to detect include
differences in DEXA equipment used in Seattle and
New Mexico and use of different methods of data collec-
tion (in person vs. mailed questionnaire) to collect
demographic, lifestyle and medical history information.
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covariate in all models and women from a range of BMI
and percent body fat levels were measured at each center.
Conclusion
This analysis suggests that circulating CRP and SAA
levels are positively associated with percent body fat and
not just greater weight. Beyond a reduction in adiposity,
changes in other modifiable factors, including weight
control, or use of NSAIDs, may help to decrease levels
of acute-phase inflammatory proteins. However, the
potential benefits or risks of NSAIDs or weight control
will require further evaluation and possible exploration
in a randomized clinical trial. Assessment of the asso-
ciation between use of NSAIDs and survival time may
be worthwhile as lower levels of CRP have been linked
with longer breast cancer survival and NSAIDs have
been suggested as an adjuvant treatment for breast
cancer [42].
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